Zymeworks (ZYME) Expected to Post Earnings on Thursday

Zymeworks (NASDAQ:ZYME) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.4881) per share and revenue of $14.6960 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.59) EPS for the quarter. The business had revenue of $2.41 million during the quarter. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%. On average, analysts expect Zymeworks to post $1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Zymeworks Stock Down 2.7%

Zymeworks stock opened at $22.01 on Thursday. The firm has a market cap of $1.61 billion, a P/E ratio of -16.07 and a beta of 1.13. The business has a fifty day moving average of $24.35 and a two-hundred day moving average of $24.50. Zymeworks has a twelve month low of $11.51 and a twelve month high of $29.75.

Zymeworks declared that its Board of Directors has initiated a share buyback plan on Thursday, May 14th that authorizes the company to repurchase $125.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Institutional Trading of Zymeworks

Several hedge funds and other institutional investors have recently made changes to their positions in the business. PharVision Advisers LLC purchased a new position in Zymeworks during the 3rd quarter worth $304,000. WINTON GROUP Ltd acquired a new position in Zymeworks during the 4th quarter valued at about $294,000. Virtus Investment Advisers LLC raised its stake in Zymeworks by 20.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,441 shares of the company’s stock valued at $275,000 after buying an additional 1,755 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Zymeworks by 50.0% in the third quarter. BNP Paribas Financial Markets now owns 15,460 shares of the company’s stock worth $264,000 after acquiring an additional 5,153 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in Zymeworks in the third quarter worth about $261,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZYME has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $46.00 price target on shares of Zymeworks in a research report on Wednesday, June 3rd. Truist Financial raised their price objective on Zymeworks from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Citigroup reiterated a “buy” rating on shares of Zymeworks in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a report on Friday, July 17th. Finally, Wells Fargo & Company increased their price target on shares of Zymeworks from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zymeworks presently has an average rating of “Moderate Buy” and a consensus price target of $37.33.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.